Skip to main content
Erschienen in: Herz 3/2013

01.05.2013 | e-Herz: Original article

Aortic elastic properties

Effects of carvedilol versus nebivolol

verfasst von: Dr. M.R. Sayin, M. Aydin, S.M. Dogan, T. Karabag, M.A. Cetiner, Z. Aktop

Erschienen in: Herz | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

Objectives

The aim of this study was to compare the effects of the new generation β-blocker anti-hypertensive drugs carvedilol and nebivolol on aortic elastic properties which are important indicators of hypertension-related morbidity and mortality.

Methods

A total of 50 patients who had been diagnosed with stage 1 hypertension according to the Joint National Committee (JNC) VII criteria and who had not received any anti-hypertensive treatment were enrolled in this study. Patients were randomized to receive either 25 mg/day carvedilol (n = 25) or 5 mg/day nebivolol (n = 25) for 3 months at the beginning of the study. Three patients (1 in the carvedilol group, 2 in the nebivolol group) who did not attend 3 month follow-up measurements were excluded from the study. The study was completed with 47 patients (25 women; mean age: 49 ±  9 years). The aortic elastic parameters such as aortic strain (AS), aortic distensibility (AD), and aortic stiffness index (ASI) were measured by echocardiography.

Results

Carvedilol and nebivolol provided a similar decline in both systolic and diastolic blood pressures (−12/−7 mmHg, p < 0.0001 and −12/−7 mmHg, p = 0.002, respectively). Both carvedilol and nebivolol induced a significant decrease in heart rate (− 15 bpm, p < 0.0001, − 17 bpm, p < 0.0001, respectively). Even though the heart rate at the end of the treatment was lower for the nebivolol group, the rate of decrease of heart rates between carvedilol and nebivolol groups was not statistically significant (p = 0.074). Both groups demonstrated improvements in the diastolic functions of the left ventricle where certain values showed more improvement for the nebivolol group. Both groups showed improvements in AS and AD rates compared to basal rates; however, these improvements were not statistically significant. Although the improvement rates in AS, AD, and ASI were higher in the nebivolol group compared to the carvedilol group, the differences were not statistically significant (p = 0.091, p = 0.095, p = 0.259, respectively).

Conclusion

Both carvedilol and nebivolol induced a decrease in blood pressure and heart rate and showed an improvement in left ventricular diastolic functions. It was observed that both drugs did not cause deterioration in the aortic elastic properties but a slight improvement was seen. However, this improvement was not statistically significant. The improvement was more explicit in the nebivolol group. It may be concluded that nebivolol is slightly superior to carvedilol in reducing heart rate and improving left ventricular diastolic functions. However, further long-term studies with larger sample sizes should be performed in order to better define the effects of both drugs.
Literatur
1.
Zurück zum Zitat Whitworth JA (2003) World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. World Health Organization, International Society of Hypertension Writing Group. J Hypertens 21:1983–1992PubMedCrossRef Whitworth JA (2003) World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. World Health Organization, International Society of Hypertension Writing Group. J Hypertens 21:1983–1992PubMedCrossRef
2.
Zurück zum Zitat Kannel WB (1996) Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA 275:1571–1576PubMedCrossRef Kannel WB (1996) Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA 275:1571–1576PubMedCrossRef
3.
Zurück zum Zitat Eren M, Gorgulu S, Uslu N et al (2004) Relation between aortic stiffness and left ventricular diastolic function in patients with hypertension, diabetes, or both. Heart 90:37–43PubMedCrossRef Eren M, Gorgulu S, Uslu N et al (2004) Relation between aortic stiffness and left ventricular diastolic function in patients with hypertension, diabetes, or both. Heart 90:37–43PubMedCrossRef
4.
Zurück zum Zitat Laurent S, Boutouyrie P, Asmar R et al (2001) Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 37:1236–1241PubMedCrossRef Laurent S, Boutouyrie P, Asmar R et al (2001) Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 37:1236–1241PubMedCrossRef
5.
Zurück zum Zitat Boutouyrie P, Tropeano AI, Asmar R et al (2002) Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients. Hypertension 39:10–15PubMedCrossRef Boutouyrie P, Tropeano AI, Asmar R et al (2002) Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients. Hypertension 39:10–15PubMedCrossRef
6.
Zurück zum Zitat European Society of Hypertension-European Society of Cardiology Guidelines Committee (2003) 2003 European Society of Hypertension- European Society of Cardiology guidelines for management of arterial hypertension. J Hypertens 21:1011–53 (Erratum in: J Hypertens 2003; 21:2203–2204 and J Hypertens 2004; 22:435) European Society of Hypertension-European Society of Cardiology Guidelines Committee (2003) 2003 European Society of Hypertension- European Society of Cardiology guidelines for management of arterial hypertension. J Hypertens 21:1011–53 (Erratum in: J Hypertens 2003; 21:2203–2204 and J Hypertens 2004; 22:435)
7.
Zurück zum Zitat Egan BM, Basile J, Chilton RJ, Cohen JD (2005) Cardioprotection: the role of beta-blocker therapy. J Clin Hypertens (Greenwich) 7:409–416 Egan BM, Basile J, Chilton RJ, Cohen JD (2005) Cardioprotection: the role of beta-blocker therapy. J Clin Hypertens (Greenwich) 7:409–416
8.
Zurück zum Zitat Weiss R (2006) Nebivolol: a novel beta-blocker with nitric oxide-induced vasodilatation. Vasc Health Risk Manag 2:303–308PubMedCrossRef Weiss R (2006) Nebivolol: a novel beta-blocker with nitric oxide-induced vasodilatation. Vasc Health Risk Manag 2:303–308PubMedCrossRef
9.
Zurück zum Zitat Sica DA (2007) Beta-blockers in hypertension: A reassessment of the benefit of combined alpha-/beta-blockade. J Clin Hypertens (Greenwich) 9:4–9 Sica DA (2007) Beta-blockers in hypertension: A reassessment of the benefit of combined alpha-/beta-blockade. J Clin Hypertens (Greenwich) 9:4–9
10.
Zurück zum Zitat Chobanian AV, Bakris GL, Black HR et al (2003) The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. J Am Med Assoc 289:2560–2572CrossRef Chobanian AV, Bakris GL, Black HR et al (2003) The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. J Am Med Assoc 289:2560–2572CrossRef
11.
Zurück zum Zitat Sahn DJ, DeMaria A, Kisslo J, WeymanA (1978) Recommendations regarding quantitations in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 58:1072–1083PubMedCrossRef Sahn DJ, DeMaria A, Kisslo J, WeymanA (1978) Recommendations regarding quantitations in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 58:1072–1083PubMedCrossRef
12.
Zurück zum Zitat Lacombe F, Dart A, Dewar E et al (1992) Arterial elastic properties in man: a comparison of echo-Doppler indices of aortic stiffness. Eur Heart J 13:1040–1045PubMed Lacombe F, Dart A, Dewar E et al (1992) Arterial elastic properties in man: a comparison of echo-Doppler indices of aortic stiffness. Eur Heart J 13:1040–1045PubMed
13.
Zurück zum Zitat Belz GG (1995) Elastic properties and Windkessel function of the human aorta. Cardiovasc Drugs Ther 9:73–83PubMedCrossRef Belz GG (1995) Elastic properties and Windkessel function of the human aorta. Cardiovasc Drugs Ther 9:73–83PubMedCrossRef
14.
Zurück zum Zitat Safar ME, Girerd X, Laurent S (1996) Structural changes of large conduit arteries in hypertension. J Hypertens 14:545–555PubMedCrossRef Safar ME, Girerd X, Laurent S (1996) Structural changes of large conduit arteries in hypertension. J Hypertens 14:545–555PubMedCrossRef
15.
Zurück zum Zitat Liao D, Arnett DK, Tyroler HA et al (1999) Arterial stiffness and the development of hypertension. The ARIC study. Hypertension 34:201–206PubMedCrossRef Liao D, Arnett DK, Tyroler HA et al (1999) Arterial stiffness and the development of hypertension. The ARIC study. Hypertension 34:201–206PubMedCrossRef
16.
Zurück zum Zitat Dart A, Silagy C, Dewar E et al (1993) Aortic distensibility and left ventricular structure and function in isolated systolic hypertension. Eur Heart J 14:1465–1470PubMedCrossRef Dart A, Silagy C, Dewar E et al (1993) Aortic distensibility and left ventricular structure and function in isolated systolic hypertension. Eur Heart J 14:1465–1470PubMedCrossRef
17.
Zurück zum Zitat Dunn CJ, Lea AP, Wagstaff AJ (1997) Carvedilol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders. Drugs 54:161–185PubMedCrossRef Dunn CJ, Lea AP, Wagstaff AJ (1997) Carvedilol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders. Drugs 54:161–185PubMedCrossRef
18.
Zurück zum Zitat Van Nueten L, Dupont AG, Vertommen C et al (1997) A dose-response trial of nebivolol in essential hypertension. J Hum Hypertens 11:139–144CrossRef Van Nueten L, Dupont AG, Vertommen C et al (1997) A dose-response trial of nebivolol in essential hypertension. J Hum Hypertens 11:139–144CrossRef
19.
Zurück zum Zitat Stoschitzky K, Stoschitzky G, Brussee H et al (2006) Comparing beta-blocking effects of bisoprolol, carvedilol and nebivolol. Cardiology 106:199–206PubMedCrossRef Stoschitzky K, Stoschitzky G, Brussee H et al (2006) Comparing beta-blocking effects of bisoprolol, carvedilol and nebivolol. Cardiology 106:199–206PubMedCrossRef
20.
Zurück zum Zitat Perret F, Mooser V, Hayoz D et al (1991) Evaluation of arterial compliance-pressure curves. Effect of antihypertensive drugs. Hypertension 18 (4 Suppl):II77–II83PubMedCrossRef Perret F, Mooser V, Hayoz D et al (1991) Evaluation of arterial compliance-pressure curves. Effect of antihypertensive drugs. Hypertension 18 (4 Suppl):II77–II83PubMedCrossRef
21.
Zurück zum Zitat Schiffrin EL, Deng LY, Larochelle P (1994) Effects of a beta-blocker or a converting enzyme inhibitor on resistance arteries in essential hypertension. Hypertension 23:83–91PubMedCrossRef Schiffrin EL, Deng LY, Larochelle P (1994) Effects of a beta-blocker or a converting enzyme inhibitor on resistance arteries in essential hypertension. Hypertension 23:83–91PubMedCrossRef
22.
Zurück zum Zitat Hirata K, Vlachopoulos C, Adji A, O’Rourke MF (2005) Benefits from angiotensin-converting enzyme inhibitor ‘beyond blood pressure lowering’: beyond blood pressure or beyond the brachial artery? J Hypertens 23:551–556PubMedCrossRef Hirata K, Vlachopoulos C, Adji A, O’Rourke MF (2005) Benefits from angiotensin-converting enzyme inhibitor ‘beyond blood pressure lowering’: beyond blood pressure or beyond the brachial artery? J Hypertens 23:551–556PubMedCrossRef
23.
Zurück zum Zitat Williams B, Lacy PS, Thom SM et al (2006) Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 113:1213–1225PubMedCrossRef Williams B, Lacy PS, Thom SM et al (2006) Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 113:1213–1225PubMedCrossRef
24.
Zurück zum Zitat Yue TL, Mckenna PJ, Lysko PG et al (1994) SB 211475, a metabolite of carvedilol, a novel antihipertensive agent, is a potent antioksidant. Eur J Pharmacol 251:237–243PubMedCrossRef Yue TL, Mckenna PJ, Lysko PG et al (1994) SB 211475, a metabolite of carvedilol, a novel antihipertensive agent, is a potent antioksidant. Eur J Pharmacol 251:237–243PubMedCrossRef
25.
Zurück zum Zitat Sponer G, Bartsch W, Strein K et al (1987) Pharmacologial profile of carvedilol as a beta-blocking agent with vasodilating and hypotensive properties. J Cardiovasc Pharmacol 9:317–327PubMedCrossRef Sponer G, Bartsch W, Strein K et al (1987) Pharmacologial profile of carvedilol as a beta-blocking agent with vasodilating and hypotensive properties. J Cardiovasc Pharmacol 9:317–327PubMedCrossRef
26.
Zurück zum Zitat Sponer G, Feuerstein GZ (1999) The adrenergic pharmacology of carvedilol. Heart Failure Rev 4:21–27CrossRef Sponer G, Feuerstein GZ (1999) The adrenergic pharmacology of carvedilol. Heart Failure Rev 4:21–27CrossRef
27.
Zurück zum Zitat Pauwels PJ, Gommeren W, Van Lommen G et al (1988) The receptor binding profile of the new antihypertensive agent nebivolol and its stereoisomers compared with various beta-adrenergic blockers. Mol Pharmacol 34:843–851PubMed Pauwels PJ, Gommeren W, Van Lommen G et al (1988) The receptor binding profile of the new antihypertensive agent nebivolol and its stereoisomers compared with various beta-adrenergic blockers. Mol Pharmacol 34:843–851PubMed
28.
Zurück zum Zitat Van de Water A, Janssens W, Van Neuten J et al (1988) Pharmacological and hemodynamic profile of nebivolol, a chemically novel, potent, and selective beta-1-adrenergic antagonist. J Cardiovasc Pharmacol 11:552–563CrossRef Van de Water A, Janssens W, Van Neuten J et al (1988) Pharmacological and hemodynamic profile of nebivolol, a chemically novel, potent, and selective beta-1-adrenergic antagonist. J Cardiovasc Pharmacol 11:552–563CrossRef
29.
Zurück zum Zitat Troost R, Schwedhelm E, Rojczyk S et al (2000) Nebivolol decreases systemic oxidative stress in healthy volunteers. Br J Clin Pharmacol 50:377–379PubMedCrossRef Troost R, Schwedhelm E, Rojczyk S et al (2000) Nebivolol decreases systemic oxidative stress in healthy volunteers. Br J Clin Pharmacol 50:377–379PubMedCrossRef
30.
Zurück zum Zitat Pannier BM, Guerin AP, Marchais SJ, London GM (2001) Different aortic reflection wave responses following long-term angiotensin-converting enzyme inhibition and beta-blocker in essential hypertension. Clin Exp Pharmacol Physiol 28:1074–1077PubMedCrossRef Pannier BM, Guerin AP, Marchais SJ, London GM (2001) Different aortic reflection wave responses following long-term angiotensin-converting enzyme inhibition and beta-blocker in essential hypertension. Clin Exp Pharmacol Physiol 28:1074–1077PubMedCrossRef
31.
Zurück zum Zitat Savolainen A, Keto P, Poutanen VP et al (1996) Effects of angiotensin-converting enzyme inhibition versus beta-adrenergic blockade on aortic stiffness in essential hypertension. J Cardiovasc Pharmacol 27:99–104PubMedCrossRef Savolainen A, Keto P, Poutanen VP et al (1996) Effects of angiotensin-converting enzyme inhibition versus beta-adrenergic blockade on aortic stiffness in essential hypertension. J Cardiovasc Pharmacol 27:99–104PubMedCrossRef
32.
Zurück zum Zitat Celik T, Iyisoy A, Acikel C et al (2008) The comparative effects of metoprolol and perindopril on aortic elasticity in young patients with prehypertension. Blood Press Monit 13:169–176PubMedCrossRef Celik T, Iyisoy A, Acikel C et al (2008) The comparative effects of metoprolol and perindopril on aortic elasticity in young patients with prehypertension. Blood Press Monit 13:169–176PubMedCrossRef
33.
Zurück zum Zitat Morgan T, Lauri J, Bertram D, Anderson A (2004) Effect of different antihypertensive drug classes on central aortic pressure. Am J Hypertens 17:118–123PubMedCrossRef Morgan T, Lauri J, Bertram D, Anderson A (2004) Effect of different antihypertensive drug classes on central aortic pressure. Am J Hypertens 17:118–123PubMedCrossRef
34.
Zurück zum Zitat London GM, Asmar RG, O’Rourke MF, Safar ME (2004) Mechanism(s) of selective systolic blood pressure reduction after a low-dose conbination of perindopril/indapamide in hypertensive subjects: comparison with atenolol. J Am Coll Cardiol 43:92–99PubMedCrossRef London GM, Asmar RG, O’Rourke MF, Safar ME (2004) Mechanism(s) of selective systolic blood pressure reduction after a low-dose conbination of perindopril/indapamide in hypertensive subjects: comparison with atenolol. J Am Coll Cardiol 43:92–99PubMedCrossRef
35.
Zurück zum Zitat Mahmud A, Feely J (2008) Beta-blockers reduce aortic stiffness in hypertension but nebivolol, not atenolol, reduces wave reflection. Am J Hypertens 21:663–667PubMedCrossRef Mahmud A, Feely J (2008) Beta-blockers reduce aortic stiffness in hypertension but nebivolol, not atenolol, reduces wave reflection. Am J Hypertens 21:663–667PubMedCrossRef
36.
Zurück zum Zitat Dhakam Z, Yasmin, McEniery CM et al (2008) A comparison of atenolol and nebivolol in isolated systolic hypertension. J Hypertens 26:351–356PubMedCrossRef Dhakam Z, Yasmin, McEniery CM et al (2008) A comparison of atenolol and nebivolol in isolated systolic hypertension. J Hypertens 26:351–356PubMedCrossRef
37.
Zurück zum Zitat McEniery CM, Schmitt M, Qasem A et al (2004) Nebivolol increases arterial distensibility in vivo. Hypertension 44:305–310PubMedCrossRef McEniery CM, Schmitt M, Qasem A et al (2004) Nebivolol increases arterial distensibility in vivo. Hypertension 44:305–310PubMedCrossRef
38.
Zurück zum Zitat Arnett DK, Evans GW, Riley WA (1994) Arterial stiffness: a new cardiovascular risk factor. Am J Epidemiol 140:669–682PubMed Arnett DK, Evans GW, Riley WA (1994) Arterial stiffness: a new cardiovascular risk factor. Am J Epidemiol 140:669–682PubMed
39.
Zurück zum Zitat Matsumoto Y, Hamada M, Hiwada K (2000) Aortic distensibility is closely related to the progression of left ventricular hypertrophy in patients receiving hemodialysis. Angiology 51:933–941PubMedCrossRef Matsumoto Y, Hamada M, Hiwada K (2000) Aortic distensibility is closely related to the progression of left ventricular hypertrophy in patients receiving hemodialysis. Angiology 51:933–941PubMedCrossRef
40.
Zurück zum Zitat Tuncer M, Guntekin U, Gunes Y et al (2008) Differential effects of nebivolol and atenolol on transmitral diastolic filling parameters in patients with essential hypertension. Adv Ther 25:619–626PubMedCrossRef Tuncer M, Guntekin U, Gunes Y et al (2008) Differential effects of nebivolol and atenolol on transmitral diastolic filling parameters in patients with essential hypertension. Adv Ther 25:619–626PubMedCrossRef
41.
Zurück zum Zitat Bergström A, Andersson B, Edner M et al (2004) Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler-echocardiographic study (SWEDIC). Eur J Heart Fail 6:453–461PubMedCrossRef Bergström A, Andersson B, Edner M et al (2004) Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler-echocardiographic study (SWEDIC). Eur J Heart Fail 6:453–461PubMedCrossRef
42.
Zurück zum Zitat Stefanadis C, Stratos C, Boudoulas H et al (1990) Distensibility of the ascending aorta: comparison of invasive and noninvasive techniques in healthy men and in men with coronary artery disease. Eur Heart J 11:990–996PubMed Stefanadis C, Stratos C, Boudoulas H et al (1990) Distensibility of the ascending aorta: comparison of invasive and noninvasive techniques in healthy men and in men with coronary artery disease. Eur Heart J 11:990–996PubMed
Metadaten
Titel
Aortic elastic properties
Effects of carvedilol versus nebivolol
verfasst von
Dr. M.R. Sayin
M. Aydin
S.M. Dogan
T. Karabag
M.A. Cetiner
Z. Aktop
Publikationsdatum
01.05.2013
Verlag
Urban and Vogel
Erschienen in
Herz / Ausgabe 3/2013
Print ISSN: 0340-9937
Elektronische ISSN: 1615-6692
DOI
https://doi.org/10.1007/s00059-012-3695-9

Weitere Artikel der Ausgabe 3/2013

Herz 3/2013 Zur Ausgabe

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.